Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

03.02.2026

Roche CT-388 Obesity Drug Posts 22.5% Weight Loss

Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.

This article is for Health Matters subscribers

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

Subscribe Log in

Biopharma Pipeline, Carmot Therapeutics, CT-388, diabetes, GIP, GLP-1, Metabolic Disease, mounjaro, Obesity Drugs, Phase 2 Trial, Phase 3 Trial, Roche, Tirzepatide, Weight Loss Market, Zepbound

More from Health Matters

10.11.2026

GLP-1 Eye Risk: FDA Orders New Warnings

The FDA orders GLP-1 eye risk warnings for diabetes and weight-loss medicines after reviewing NAION evidence. Read what the changes mean for care.

08.11.2026

Xtandi Patent Dispute Heads to Constitutional Court

The Xtandi patent dispute reaches South Africa’s Constitutional Court on 23 November. Read what is at stake for generic access and damages claims.

06.11.2026

Pharmaceutical Sovereignty Put to the Test by Ebola

Pharmaceutical sovereignty is back in focus as Ebola spreads in the DRC. See how pooled procurement and shared regulation could secure supplies.